Generics in Italy

Date: January 4, 2016
Pages: 34
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G6778DBBE30EN
Leaflet:

Download PDF Leaflet

Generics in Italy
INTRODUCTION

Generics in Italy industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Italy generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

HIGHLIGHTS
  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Italian generics market is expected to generate total revenues of $1.4bn in 2015, representing a compound annual growth rate (CAGR) of 11.9% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 19.5 % of total pharma volume in 2015.
  • The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.8% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $1.9bn by the end of 2020.
FEATURES
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Italy
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Italy
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Italy generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the Italy economy
KEY QUESTIONS ANSWERED
  • What was the size of the Italy generics market by value in 2015?
  • What will be the size of the Italy generics market in 2020?
  • What factors are affecting the strength of competition in the Italy generics market?
  • How has the market performed over the last five years?
  • How large is Italy’s generics market in relation to its regional counterparts?
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country Data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Italy generics market value: $ million, 2011–15(e)
Table 2: Italy generics market volume: % of total pharma volume, 2011–15(e)
Table 3: Italy generics market geography segmentation: $ billion, 2015(e)
Table 4: Italy generics market value forecast: $ million, 2015–20
Table 5: Italy generics market volume forecast: % of total pharma volume, 2015–20
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: Italy size of population (million), 2011–15
Table 18: Italy gdp (constant 2005 prices, $ billion), 2011–15
Table 19: Italy gdp (current prices, $ billion), 2011–15
Table 20: Italy inflation, 2011–15
Table 21: Italy consumer price index (absolute), 2011–15
Table 22: Italy exchange rate, 2011–15

LIST OF FIGURES

Figure 1: Italy generics market value: $ million, 2011–15(e)
Figure 2: Italy generics market volume: % of total pharma volume, 2011–15(e)
Figure 3: Italy generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Italy generics market value forecast: $ million, 2015–20
Figure 5: Italy generics market volume forecast: % of total pharma volume, 2015–20
Figure 6: Forces driving competition in the generics market in Italy, 2015
Figure 7: Drivers of buyer power in the generics market in Italy, 2015
Figure 8: Drivers of supplier power in the generics market in Italy, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Italy, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Italy, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Italy, 2015
Figure 12: Mylan Inc.: revenues & profitability
Figure 13: Mylan Inc.: assets & liabilities
Figure 14: Sanofi SA: revenues & profitability
Figure 15: Sanofi SA: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Skip to top


Emerging Generic Drug Markets in Europe US$ 1,390.00 Dec, 2007 · 196 pages
The World Generic Market Report 2012 US$ 1,390.00 Mar, 2012 · 552 pages

Ask Your Question

Generics in Italy
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: